Genomics · 2026
Alternative splicing signatures correlate with disease severity and clinical subtypes in primary Sjögren's syndrome.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Jiaxu, Shi Zhenghao, Cao Jingyuan, Wu Xiangxiang, Li Guoling, Li Ben, Hou Jiaqi, Xue Luan
Аннотация
Primary Sjögren's Syndrome (pSS) is a chronic, systemic autoimmune disease characterized by sicca symptoms due to exocrine gland involvement, but also presenting with a wide range of extraglandular manifestations and diverse subjective burdens, leading to significant clinical heterogeneity that complicates accurate diagnosis and objective assessment of disease activity. While transcriptome sequencing technologies have revolutionized the global analysis of alternative splicing (AS) events and aberrant AS has been implicated in the pathogenesis of various autoimmune diseases, research into AS in pSS remains limited to individual genes. Therefore, this study analyzed peripheral blood transcriptomes from pSS patients and healthy controls, utilizing key co-expression module eigengene values to stratify patients into homogeneous subgroups. Clear differential AS analysis was further obtained. Ten genes with significant AS events were identified, with AS in WARS1, OASL, DDX60, C2, RMI2, PALM2AKAP2, and MYO7B significantly associated with various laboratory indicators. Furthermore, by combining expression and usage rate changes with protein sequence structure predictions, their detailed functional implications in pSS were fully discussed. In conclusion, novel AS signatures significantly associated with pSS severity were revealed, which may serve as potential biomarkers for disease stratification and therapeutic targets in pSS, further providing opportunities for mechanistic research.